Miguel Fernández-Zarzoso

Immunotherapy for the treatment of Hodgkin lymphoma

J. de la Rubia, E. Donato, Miguel Fernández-Zarzoso, 2017, Expert review of hematology.

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

J. de la Rubia, I. Gómez-Seguí, Miguel Fernández-Zarzoso, 2020, Expert review of hematology.

Therapeutic plasma exchange: Review of current indications.

J. de la Rubia, I. Gómez-Seguí, Miguel Fernández-Zarzoso, 2019, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Choroidal lymphoma diagnosed by polymerase chain reaction–based clonality assessment

L. Martínez-Costa, Elena Gómez-Beltrán, Miguel Fernández-Zarzoso, 2020, European journal of ophthalmology.

Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I

E. Gras-Colomer, M. Merino-Sanjuán, M. Climente-Martí, 2018, Basic & clinical pharmacology & toxicology.

Cellular Uptake of Glucocerebrosidase in Gaucher Patients Receiving Enzyme Replacement Treatment

E. Gras-Colomer, M. Merino-Sanjuán, M. Climente-Martí, 2016, Clinical Pharmacokinetics.

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).

P. Abrisqueta, J. Delgado, M. Terol, 2021, Clinical lymphoma, myeloma & leukemia.

Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review

J. de la Rubia, E. Donato, Miguel Fernández-Zarzoso, 2018, OncoTargets and therapy.

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

E. González-Barca, Marcos González, M. Sánchez-Beato, 2021, PloS one.